Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Cambrex Reports Fourth Quarter and Full Year 2010 Results


      News provided by

      Cambrex Corporation

      Feb 10, 2011, 04:15 ET

      Share this article

      Share this article


      EAST RUTHERFORD, N.J., Feb. 10, 2011 /PRNewswire/ -- Cambrex Corporation (NYSE: CBM) reports fourth quarter and full year results for the period ended December 31, 2010.

      Highlights

      • Reported sales increased by 8.2%, and excluding the impact of foreign currency, sales increased 9.2% compared to fourth quarter 2009.
      • Adjusted EBITDA was $14.5 million in the fourth quarter 2010, an increase of 54% compared to $9.4 million of EBITDA in the fourth quarter of 2009.
      • Debt, net of cash was $86.3 million at the end of the fourth quarter 2010, an improvement of $4.2 million excluding $19.9 million of M&A related costs and a positive $0.9 million currency impact on foreign cash balances during the fourth quarter.
      • Cambrex Zenara began supplying product for the launch of smoking cessation gum in India and received a Certificate of Good Manufacturing Practice (GMP) for its Hyderabad, India facility, following a successful audit, allowing shipment to all EU countries.
      • Appointed Shawn Cavanagh as Chief Operating Officer in January 2011.
      • 2011 sales are expected to increase 3% to 7%, excluding the impact of currency, and EBITDA is expected to be $43 to $49 million (see Guidance section of this release).

      Basis of Reporting

      The Company has provided a reconciliation from adjusted amounts to GAAP amounts at the end of this press release.  Management believes that the adjusted amounts provide a more meaningful representation of the Company's operating results for the periods presented due to the magnitude and nature of certain expenses recorded.

      Fourth Quarter 2010 Operating Results – Continuing Operations

      Fourth quarter 2010 sales of $63.5 million were 8.2% higher than the fourth quarter 2009.  Excluding a 1.0% unfavorable impact of foreign exchange, reflecting a stronger U.S. dollar, sales increased 9.2%.  The increase is primarily due to the timing of orders for certain products, increases in sales of an active pharmaceutical ingredient ("API") to a customer who resolved their supply chain disruption which had reduced Cambrex's sales volumes for the first three quarters of the year, higher sales of a recently approved product, higher volumes of APIs for nicotine replacement therapy ("NRT") products, and higher volumes of generic APIs.  These increases were partially offset by lower controlled substances shipments during the fourth quarter of 2010.

      Fourth quarter 2010 Gross Margin increased to 32.0% from 24.7% during the fourth quarter 2009, with foreign currency favorably impacting gross margin by 1.1% in the fourth quarter 2010.  Gross margins were positively impacted by favorable product mix, lower production costs, insurance proceeds related to a business interruption claim and fees related to the cancellation of a supply contract, partially offset by lower pricing and an increase in inventory reserves.

      Selling, General and Administrative Expenses in the fourth quarter 2010 were $9.2 million compared to $8.8 million in the same period last year.  The increase is a result of a benefit due to the termination of certain postretirement benefits recorded in the fourth quarter 2009 and higher bad debt expense related to one customer in the fourth quarter 2010 partially offset by lower legal fees and insurance expense in the fourth quarter 2010.

      Research and Development ("R&D") Expenses increased to $2.4 million in the fourth quarter 2010 from $2.0 million in the fourth quarter 2009 primarily due to the March 2010 acquisition of IEP, reduced utilization of certain R&D personnel on revenue-generating custom development projects resulting in these costs being expensed rather than absorbed into cost of sales or inventory, and the development of new products and technology platforms.

      Operating Profit increased to $8.4 million in the fourth quarter 2010 from $3.7 million in the fourth quarter 2009.  Adjusted Operating Profit was $8.7 million compared to $3.7 million for the fourth quarter last year.  The increase in Adjusted Operating Profit was driven primarily by higher gross profits described above.

      Net Interest Expense decreased to $0.8 million in the fourth quarter 2010 from $1.2 million in fourth quarter 2009.  This decrease is primarily due to the Company's interest rate swaps maturing in October 2010.

      The Provision for Income Taxes totaled $1.5 million in the fourth quarter 2010.  The Company's effective tax rate has been and is expected to remain highly sensitive to the geographic mix of income due to the Company's inability to recognize tax benefits where there has been a recent history of losses, primarily in the U.S.

      Income from Continuing Operations for the fourth quarter 2010 was $5.2 million or $0.18 per share compared to a loss of $2.8 million or $0.09 per share in the fourth quarter 2009.

      Capital expenditures and depreciation for the fourth quarter 2010 were $4.1 million and $5.8 million compared to $2.9 million and $5.7 million in the fourth quarter 2009, respectively.

      Steven M. Klosk, President and Chief Executive Officer, said, "We are pleased with our fourth quarter performance which resulted in the business exceeding the high end of our recent profit guidance.  These results reflect the positive impact of the timing of orders for certain larger products, as well as continued increases in generic revenues and order patterns, and slightly higher custom development revenues.  Product mix, production costs, and cash generation were all positive for the quarter.

      "During the fourth quarter and early in 2011, we had several key events.  We announced that Cambrex Zenara began to supply finished dosage form NRT product for the launch of smoking cessation gum in India and received regulatory approval to sell product into the EU.  We signed an agreement with a Chinese partner to develop several new generic products in 2011, and Shawn Cavanagh joined the company as COO to help us accelerate our new product and strategic growth plans.

      "Our guidance for 2011 reflects a mid single digit percentage increase in sales.  We expect to see volume gains in nicotine replacement therapy APIs, albeit at lower prices, higher sales of a product that was approved in 2009, an increase in sales of a couple of our larger APIs, and continued moderate sales growth of generic APIs.  I am pleased with the direction our top line should take in 2011 and convinced that we are focused on the right strategic opportunities to position the Company for profitable growth."

      Guidance – Continuing Operations

      The Company currently expects that sales for 2011, excluding the impact of foreign currency, will increase between 3% and 7% versus 2010, and that full year 2011 EBITDA will be between $43 and $49 million.  EBITDA guidance is for continuing operations and excludes the impact of any M&A or restructuring activities.  The above guidance does not reflect Cambrex Zenara, which will be accounted for using the equity method, and as such will not be consolidated into the Company's results.  Cambrex's income statement will reflect 51% of Cambrex Zenara's net results.  For 2011, Cambrex Zenara is expected to have revenues in the low to mid single digit millions and a small EBITDA loss.

      Capital expenditures are expected to be approximately $14 to $17 million and depreciation is expected to be $21 to $23 million in 2011.

      The financial information contained in this press release is unaudited, subject to revision and should not be considered final until the 2010 Form 10-K is filed with the SEC.

      Conference Call and Webcast

      The Conference Call to discuss fourth quarter 2010 results will begin at 8:30 a.m. Eastern Time on Friday, February 11, 2011 and last approximately 45 minutes.  Those wishing to participate should call 1-888-587-0613 for domestic and +1-719-325-2370 for international.  Please use the pass code 7901037 and call approximately 10 minutes prior to start time.  A webcast is available from the Investors section on the Cambrex website located at www.cambrex.com and can be accessed for 30 days following the conference call.  A telephone replay of the conference call will be available through Friday, February 18, 2011 by calling 1-888-203-1112 for domestic and +1-719-457-0820 for international.  Please use the pass code 7901037 to access the replay.  

      Forward Looking Statements

      This document may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding expected performance, especially expectations with respect to sales, research and development expenditures, earnings per share, capital expenditures, acquisitions, divestitures, collaborations, or other expansion opportunities.  These statements may be identified by the fact that they use words such as "expects," "anticipates," "intends," "estimates," "believes" or similar expressions.  Any forward-looking statements contained herein are based on current plans and expectations and involve risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations.  The factors described in Item 1A of Part I of the Company's Annual Report on Form 10-K captioned "Risk Factors," or otherwise described in the Company's filings with the Securities and Exchange Commission, as well as any cautionary language in the Company's Annual Report on Form 10-K, provide examples of such risks and uncertainties that may cause the Company's actual results to differ materially from the expectations the Company describes in its forward-looking statements, including but not limited to, pharmaceutical outsourcing trends, competitive pricing or product developments, government legislation and regulations (particularly environmental issues), tax rate, interest rate, technology, manufacturing and legal issues, including the outcome of outstanding litigation disclosed in the Company's public filings, changes in foreign exchange rates, uncollectable receivables, loss on disposition of assets, cancellation or delays in renewal of contracts, lack of suitable raw materials or packaging materials, and the Company's ability to receive regulatory approvals for its products.

      For further details and a discussion of these and other risks and uncertainties, investors are cautioned to review the Cambrex 2009 Annual Report on Form 10-K, including the Forward-Looking Statement section therein, and other filings with the U.S. Securities and Exchange Commission.  

      About Cambrex

      Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics.  We offer Active Pharmaceutical Ingredients ("APIs"), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Our development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products.  For more information, please visit www.cambrex.com.  

      CAMBREX CORPORATION

      Statements of Profit and Loss

      For the Quarters Ended December 31, 2010 and 2009

      (in thousands)













      2010


      2009





      % of





      % of



      Amount


      Sales



      Amount


      Sales











      Gross Sales

      $

      63,522


      100.0%


      $

      58,709


      100.0%

          Commissions, Allowances and Rebates


      341


      0.5%



      779


      1.3%

      Net Sales


      63,181


      99.5%



      57,930


      98.7%











          Other Revenues


      1,727


      2.7%



      (63)


      -0.1%











      Net Revenues


      64,908


      102.2%



      57,867


      98.6%











          Cost of Goods Sold


      44,578


      70.2%



      43,353


      73.9%











      Gross Profit


      20,330


      32.0%



      14,514


      24.7%











      Operating Expenses










          Selling, General and Administrative Expenses


      9,240


      14.5%



      8,822


      15.0%

          Research and Development Expenses


      2,399


      3.8%



      2,005


      3.4%

          Restructuring Expenses


      106


      0.2%



      -


      0.0%

          Merger and Acquisition Expenses


      211


      0.3%



      -


      0.0%

      Total Operating Expenses


      11,956


      18.8%



      10,827


      18.4%











      Operating Profit


      8,374


      13.2%



      3,687


      6.3%











      Other Expenses/(Income):










          Interest Expense, net


      789


      1.2%



      1,224


      2.1%

          Other Expense/(Income), net


      527


      0.8%



      (502)


      -0.9%

          Equity in Losses of Partially-Owned Affiliate


      286


      0.5%



      -


      0.0%











      Income Before Income Taxes


      6,772


      10.7%



      2,965


      5.1%











          Provision for Income Taxes


      1,528


      2.4%



      5,733


      9.8%











      Income/(Loss) from Continuing Operations

      $

      5,244


      8.3%


      $

      (2,768)


      -4.7%











      Loss from Discontinued Operations


      (597)


      -1.0%



      -


      0.0%











      Net Income/(Loss)

      $

      4,647


      7.3%


      $

      (2,768)


      -4.7%











      Basic Earnings/(Loss) per Share of Common Stock:










        Income/(Loss) from Continuing Operations

      $

      0.18




      $

      (0.09)



        Loss from Discontinued Operations

      $

      (0.02)




      $

      -



       Net Income/(Loss)

      $

      0.16




      $

      (0.09)













      Diluted Earnings/(Loss) per Share of Common Stock:










        Income/(Loss) from Continuing Operations

      $

      0.18




      $

      (0.09)



        Loss from Discontinued Operations

      $

      (0.02)




      $

      -



       Net Income/(Loss)

      $

      0.16




      $

      (0.09)













      Weighted Average Shares Outstanding










          Basic


      29,420





      29,286



          Diluted


      29,489





      29,286





      CAMBREX CORPORATION

      Statements of Profit and Loss

      For the Twelve Months Ended December 31, 2010 and 2009

      (in thousands)













      2010


      2009





      % of





      % of



      Amount


      Sales



      Amount


      Sales











      Gross Sales

      $

      226,436


      100.0%


      $

      236,277


      100.0%

          Commissions, Allowances and Rebates


      1,545


      0.7%



      1,402


      0.6%

      Net Sales


      224,891


      99.3%



      234,875


      99.4%











          Other Revenues


      2,101


      0.9%



      (325)


      -0.1%











      Net Revenues


      226,992


      100.2%



      234,550


      99.3%











          Cost of Goods Sold


      160,126


      70.7%



      164,272


      69.6%











      Gross Profit


      66,866


      29.5%



      70,278


      29.7%











      Operating Expenses










          Selling, General and Administrative Expenses


      34,024


      15.0%



      35,711


      15.1%

          Research and Development Expenses


      10,305


      4.6%



      7,929


      3.3%

          Restructuring Expenses


      1,293


      0.6%



      -


      0.0%

          Merger and Acquisition Expenses


      997


      0.4%



      -


      0.0%

      Total Operating Expenses


      46,619


      20.6%



      43,640


      18.4%











      Operating Profit


      20,247


      8.9%



      26,638


      11.3%











      Other Expenses/(Income):










          Interest Expense, net


      4,391


      1.9%



      4,634


      2.0%

          Other Expense/(Income), net


      596


      0.3%



      (641)


      -0.3%

          Equity in Losses of Partially-Owned Affiliate


      286


      0.1%



      -


      0.0%











      Income Before Income Taxes


      14,974


      6.6%



      22,645


      9.6%











          Provision for Income Taxes


      5,665


      2.5%



      12,253


      5.2%











      Income from Continuing Operations

      $

      9,309


      4.1%


      $

      10,392


      4.4%











      Income from Discontinued Operations


      338


      0.2%



      -


      0.0%











      Net Income

      $

      9,647


      4.3%


      $

      10,392


      4.4%











      Basic Earnings per Share of Common Stock:










        Income from Continuing Operations

      $

      0.32




      $

      0.36



        Income from Discontinued Operations

      $

      0.01




      $

      -



       Net Income

      $

      0.33




      $

      0.36













      Diluted Earnings per Share of Common Stock:










        Income from Continuing Operations

      $

      0.32




      $

      0.36



        Income from Discontinued Operations

      $

      0.01




      $

      -



       Net Income

      $

      0.33




      $

      0.36













      Weighted Average Shares Outstanding










          Basic


      29,361





      29,241



          Diluted


      29,468





      29,267





      CAMBREX CORPORATION

      Reconciliation of GAAP to non-GAAP Results

      For the Quarters and Twelve Months Ended December 31, 2010 and 2009

      (in thousands)









      Fourth Quarter 2010



      Fourth Quarter 2009








      Operating Profit, as Reported

      $

      8,374



      $

      3,687








      Restructuring Expenses


      106




      -








      Merger and Acquisition Expenses


      211




      -








      Adjusted Operating Profit


      8,691




      3,687








      Depreciation and Amortization


      5,831




      5,731








      Adjusted EBITDA

      $

      14,522



      $

      9,418



















































      Twelve Months 2010



      Twelve Months 2009








      Operating Profit, as Reported

      $

      20,247



      $

      26,638








      Restructuring Expenses


      1,293




      -








      Merger and Acquisition Expenses


      997




      -








      Adjusted Operating Profit


      22,537




      26,638








      Depreciation and Amortization


      21,828




      20,505








      Adjusted EBITDA

      $

      44,365



      $

      47,143



      CAMBREX CORPORATION

      Consolidated Balance Sheets

      As of December 31, 2010 and 2009

      (in thousands)















      December 31,



      December 31,

      Assets


      2010



      2009







      Cash and Cash Equivalents

      $

      29,614


      $

      52,365

      Trade Receivables, net


      39,025



      32,025

      Inventories, net


      61,408



      58,369

      Prepaid Expenses and Other Current Assets


      5,082



      6,654

       Total Current Assets


      135,129



      149,413







      Property, Plant and Equipment, net


      150,483



      161,149

      Goodwill


      37,694



      36,360

      Intangibles Assets, net


      4,687



      -

      Investment in Partially-Owned Affiliate


      19,709



      -

      Other Non-Current Assets


      4,049



      4,593







       Total Assets

      $

      351,751


      $

      351,515







      Liabilities and Stockholders' Equity












      Accounts Payable

      $

      19,480


      $

      17,038

      Accrued Expenses and Other Current Liabilities


      33,503



      38,013

       Total Current Liabilities


      52,983



      55,051







      Long-term Debt


      115,900



      120,800

      Deferred Income Taxes


      17,893



      17,305

      Accrued Pension and Postretirement Benefits


      43,921



      40,963

      Other Non-Current Liabilities


      13,419



      14,126







       Total Liabilities

      $

      244,116


      $

      248,245







       Stockholders’ Equity

      $

      107,635


      $

      103,270







       Total Liabilities and Stockholders’ Equity

      $

      351,751


      $

      351,515



      SOURCE Cambrex Corporation

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.